<DOC>
	<DOC>NCT01404169</DOC>
	<brief_summary>The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.</brief_summary>
	<brief_title>A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria Written informed consent (IC) will be obtained from the subject (if possible) or from the subject's legal guardian or legal representative prior to beginning screening activities. Subject age range: male and female subjects 50 to 90 years of age, inclusive Diagnosis: diagnostic evidence of probable Alzheimer's Disease (AD) consistent with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) and National Institute of Neurological and Communicative Disorders and StrokeAlzheimer's Disease and Related Disorders Association (NINCDSADRDA) criteria MMSE 1 to 12 inclusive, at both Screening and Baseline SIB less than or equal to 90 and greater than or equal to 10 at both Screening and Baseline Comorbid medical conditions must be clinically stable prior to Baseline, unless otherwise specified. Exclusion Criteria Subjects with a known history of disorders that affect cognition or the ability to assess cognition, but are distinguishable from AD Evidence of focal disease to account for dementia on any cranial image MRI or CT. Subjects with dementia complicated by other organic disease or AD with delirium according to DSMIV criteria Subjects who cannot swallow or who have difficulty swallowing whole tablets, as tablets should not be broken or crushed Illiteracy prior to AD Subjects who are unwilling or unable to fulfill the requirements of the study Treatment with another cholinesterase inhibitor and/or memantine in the 3 months prior to Screening Subjects with a poor response (tolerability) to prior exposure to donepezil</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Delirium</keyword>
	<keyword>Amnestic</keyword>
	<keyword>Cognitive Disorders</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Tauopathies</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Cholinesterase Inhibitors</keyword>
	<keyword>Enzy</keyword>
</DOC>